Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for its NxTAG® Respiratory Pathogen Panel that detects 20 clinically relevant viral and bacterial respiratory ...

The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident ...

CORALVILLE, Iowa--(BUSINESS WIRE)--To meet customer demand for a multiplexed, multiple respiratory disease target panel that provides comprehensive genome coverage, Integrated DNA Technologies (IDT) ...

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode, a leader in innovative molecular diagnostic solutions, announced today the submission of a new nucleic acid extraction claim for the ...

Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for its NxTAG® Respiratory Pathogen Panel. The Panel detects 21 clinically-relevant viral and bacterial ...

Applied BioCode, a leader in multiplex molecular diagnostic solutions, today announced a significant enhancement to its BioCode® Respiratory Pathogen Panel (RPP) workflow with the addition of nucleic ...

This webinar will explore how microfluidic singleplex qPCR enables simultaneous detection of multiple respiratory pathogens across diverse sample types in surveillance settings. We'll begin with an ...

New ready-to-ship xGen™ NGS solution will enable researchers to combat challenging diseases of today and prepare for the next pathogen of tomorrow Integrated DNA Technologies is revealing a new next ...

Applied BioCode, a leader in innovative molecular diagnostic solutions, announced today the submission of a new nucleic acid extraction claim for the KingFisher™ Flex Nucleic Acid Purification System ...